Advances of Molecular Imaging Probes for the Diagnosis of Alzheimer's Disease

ISSN: 1875-5828 (Online)
ISSN: 1567-2050 (Print)

Volume 14, 12 Issues, 2017

Download PDF Flyer

Current Alzheimer Research

This journal supports open access

Aims & ScopeAbstracted/Indexed in

Ranking and Category:
  • 59th of 192 in Clinical Neurology
  • 101st of 256 in Neurosciences

Submit Abstracts Online Submit Manuscripts Online

Prof. Debomoy K. Lahiri
Department of Psychiatry, Indiana University School of Medicine
Neuroscience Research Center
Indianapolis, IN 46202

View Full Editorial Board

Subscribe Purchase Articles Order Reprints

Current: 3.145
5 - Year: 3.58

Advances of Molecular Imaging Probes for the Diagnosis of Alzheimer's Disease

Current Alzheimer Research, 11(3): 221-231.

Author(s): Ming Zhou, Xiaobo Wang, Zhiguo Liu, Lun Yu, Shuo Hu, Lizhang Chen and Wenbin Zeng.

Affiliation: School of Pharmaceutical Sciences, Central South University, Changsha 410013, China.


Alzheimer's disease (AD) is a neurodegenerative disorder characterized by progressive decline in multiple cognitive domains and it becomes the most common cause of dementia in the elderly. There is an urgent need for the early diagnosis and treatment of AD to ease caregiver burden and medical costs, as well as improve patients’ living activities associated with the dramatic increasing number of affected individuals. Molecular imaging with target-specific probes is contributing to identify the underlying biology in AD, which benefits to the early diagnosis of AD and the evaluation of anti-AD therapy. Molecular imaging probes, such as 11C-PIB, 11C-MP4A, 18F-AV-45, and 11F-FDG, can selectively bind to special bimolecular of AD or accurately accumulate at the location of damage areas, thus become an edge tool for a better management of the diseases in the clinical practice and new drug development. In the past decades, a large variety of probes is being developed and tested to be useful for the early and accurate diagnosis of Alzheimer's disease, patient selection for disease-modifying therapeutic trials and monitoring the effect of anti-amyloid therapy. Since imaging probes may also help to guide physicians to identify those patients that could best benefit from a given therapeutic regimen, dose, or duration of drug, this paper is to present a perspective of the available imaging probes for AD, classified on different modalities. Meanwhile, recent advances of those probes that have been selected for clinical trials and are at the different stages of the US Food and Drugs Administration (FDA) approval are outlined. Additionally, future directions and specific application of imaging strategies designed for both diagnosis and treatment for AD are discussed.


Alzheimer's disease, biomarker, molecular imaging, PET, probe.

Purchase Online Order Reprints Order Eprints Rights and Permissions

Article Details

Volume: 11
Issue Number: 3
First Page: 221
Last Page: 231
Page Count: 11
DOI: 10.2174/1567205011666140131121259
Price: $58

Related Journals

Webmaster Contact: Copyright © 2016 Bentham Science